TIMP-1 and VEGF-165 Serum Concentration During First-Line Therapy of Ovarian Cancer Patients
BMC Cancer - United Kingdom
doi 10.1186/1471-2407-10-139
Full Text
Open PDFAbstract
Available in full text
Date
April 13, 2010
Authors
Publisher
Springer Science and Business Media LLC